Gland Pharma Share Price

The revenue for the September 2022 quarter is pegged at Rs. 10483.09 millions against Rs. 10804.69 millions recorded during the year-ago period.The Company's Net profit for the September 2022 quarter have declined marginally to Rs. 2396.30  millions as against Rs. 3021.20 millions reported during the corresponding quarter ended.A decline of 3608.59 millions was observed in the OP in the quarter ended September 2022 from 4278.38 millions on QoQ basis.

Net sales declined -12.92%  to  Rs. 9258.99 million from Rs. 10633.25 millions.The Net Profit of the company registered a slight decline of -16.77% to Rs. 2275.36  millions from Rs. 2733.84 millions.The company reported a degrowth in operating Profit to 3454.67 millions from 3949.35 millions.

The sales is pegged at Rs. 9258.99 millions for the December 2022 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 10633.25 millions during the year-ago period.The Net Profit of the company registered a slight decline of -16.77% to Rs. 2275.36  millions from Rs. 2733.84 millions.The company reported a degrowth in operating Profit to 3454.67 millions from 3949.35 millions.

The sales is pegged at Rs. 9258.99 millions for the December 2022 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 10633.25 millions during the year-ago period.The Net Profit of the company registered a slight decline of -16.77% to Rs. 2275.36  millions from Rs. 2733.84 millions.The company reported a degrowth in operating Profit to 3454.67 millions from 3949.35 millions.

Pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, Gland Pharma has informed that it enclosed the schedule of Analyst/ Institutional Investor Meetings with the Company. The schedule of the above-mentioned meetings is subject to change and the change may occur due to exigencies on the part of the Investor/ Analyst/ Company.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, Gland Pharma has informed that it enclosed the schedule of Analyst/ Institutional Investor Meetings with the Company. The schedule of the above-mentioned meetings is subject to change and the change may occur due to exigencies on the part of the Investor/ Analyst/ Company.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, Gland Pharma has informed that the Analyst/ Institutional Investor Meeting with SBI Mutual Fund held on 26th December 2022 in the form of in-person, One on One meeting. The schedule of the above-mentioned meeting is subject to change and the change may occur due to exigencies on the part of the Investor/ Analyst/ Company.

The above information is a part of company’s filings submitted to BSE.

The company has receivied EIR from US FDA for Dundigal Facility at Hyderabad

Gland Pharma is currently trading at Rs. 1584.50, up by 7.50 points or 0.48% from its previous closing of Rs. 1577.00 on the BSE.

The scrip opened at Rs. 1577.05 and has touched a high and low of Rs. 1598.80 and Rs. 1566.05 respectively. So far 11868 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 4060.00 on 06-Jan-2022 and a 52 week low of Rs. 1553.80 on 29-Dec-2022.

Last one week high and low of the scrip stood at Rs. 1617.00 and Rs. 1553.80 respectively. The current market cap of the company is Rs. 26054.82 crore.

The promoters holding in the company stood at 57.86%, while Institutions and Non-Institutions held 28.01% and 14.13% respectively.

Gland Pharma has received the Establishment Inspection Report (EIR) from the Office of Product Evaluation and Quality Center for Devices and Radiological Health, US FDA indicating closure of the inspection at Dundigal Facility in Hyderabad. Earlier, the Pre-Market Inspection covering US FDA’s Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) at the company’s Dundigal Facility at Hyderabad was conducted from  August 22, 2022 to  August 25, 2022. The company had received 1 observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Total income of the company decreased by 9.85% to Rs 999.80 crore for Q3FY23

Gland Pharma is currently trading at Rs. 1424.30, up by 67.30 points or 4.96% from its previous closing of Rs. 1357.00 on the BSE.

The scrip opened at Rs. 1350.05 and has touched a high and low of Rs. 1431.45 and Rs. 1350.05 respectively. So far 33210 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 3599.00 on 07-Feb-2022 and a 52 week low of Rs. 1309.00 on 24-Jan-2023.

Last one week high and low of the scrip stood at Rs. 1429.90 and Rs. 1309.00 respectively. The current market cap of the company is Rs. 23402.48 crore.

The promoters holding in the company stood at 57.86%, while Institutions and Non-Institutions held 27.79% and 14.34% respectively.

Gland Pharma has reported fall of 16.77% in its net profit at Rs 227.54 crore for third quarter ended December 31, 2022 as compared to Rs 273.38 crore for the corresponding quarter previous year. Total income of the company decreased by 10.96% to Rs 987.41 crore for the quarter under review as compared to Rs 1,108.99 crore for the same quarter in the previous year.

On the consolidated basis, the company has reported fall of 15.05% in its net profit at Rs 231.95 crore for third quarter ended December 31, 2022 as compared to Rs 273.03 crore for the same quarter in the previous year. Total income of the company decreased by 9.85% to Rs 999.80 crore for the quarter under review as compared to Rs 1,108.99 crore for the same quarter in the previous year.

Pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, Gland Pharma has informed that the Analyst/ Institutional Investor Meeting will be held on 10th February 2023 with Graticule Asset Management Asia in the form of One on One meeting. The schedule of the above-mentioned meeting is subject to change and the change may occur due to exigencies on the part of the Investor/ Analyst/ Company.

The above information is a part of company’s filings submitted to BSE.

The expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places

Gland Pharma is currently trading at Rs. 1333.90, up by 28.60 points or 2.19% from its previous closing of Rs. 1305.30 on the BSE.

The scrip opened at Rs. 1315.90 and has touched a high and low of Rs. 1347.45 and Rs. 1304.10 respectively. So far 13858 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 3556.10 on 21-Apr-2022 and a 52 week low of Rs. 1169.75 on 06-Feb-2023.

Last one week high and low of the scrip stood at Rs. 1368.25 and Rs. 1290.05 respectively. The current market cap of the company is Rs. 21968.03 crore.

The promoters holding in the company stood at 57.86%, while Institutions and Non-Institutions held 27.79% and 14.34% respectively.

Gland Pharma is planning to invest Rs 400 crore to create additional capabilities in its existing facility at Genome Valley in Telangana to manufacture biologicals, biosimilar, antibodies and recombinant Insulin.

The expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places. The company had established their biopharmaceutical facility in February last year at Genome Valley with an investment of Rs 300 crore to manufacture vaccines, biologicals, biosimilar, antibodies and others. The expanded site is envisaged to meet the national and international regulations to be followed in the manufacturing of the biological products as applicable and shall be built under the GMP guidelines applicable for the respective product lines.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

The company is planning to invest Rs 400 crore to expand Telangana’s existing facility

Gland Pharma is currently trading at Rs. 1335.25, up by 5.45 points or 0.41% from its previous closing of Rs. 1329.80 on the BSE.

The scrip opened at Rs. 1320.05 and has touched a high and low of Rs. 1356.75 and Rs. 1320.05 respectively. So far 12180 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 3556.10 on 21-Apr-2022 and a 52 week low of Rs. 1169.75 on 06-Feb-2023.

Last one week high and low of the scrip stood at Rs. 1356.75 and Rs. 1290.05 respectively. The current market cap of the company is Rs. 21979.56 crore.

The promoters holding in the company stood at 57.86%, while Institutions and Non-Institutions held 27.79% and 14.34% respectively.

Gland Pharma is planning to invest Rs 400 crore to create additional capabilities in its existing facility at Genome Valley in Telangana to manufacture biologicals, biosimilar, antibodies and recombinant Insulin.

The expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places. The company had established their biopharmaceutical facility in February last year at Genome Valley with an investment of Rs 300 crore to manufacture vaccines, biologicals, biosimilar, antibodies and others. The expanded site is envisaged to meet the national and international regulations to be followed in the manufacturing of the biological products as applicable and shall be built under the GMP guidelines applicable for the respective product lines.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Quarterly Results

Quarterly Results

Audited Results

Quarterly Results

Quarterly Results

Quarterly Results

Audited Results

Quarterly Results

Total consolidated income of the company decreased by 1.91% at Rs 1110.03 crore for Q2FY23

Gland Pharma has reported results for second quarter ended September 30, 2022.

The company has reported a fall of 20.68% in its net profit at Rs 239.63 crore for the quarter under review as compared to Rs 302.12 crore for the same quarter in the previous year. Total income of the company decreased by 1.57% at Rs 1113.93 crore for Q2FY23 as compared Rs 1131.67 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported fall of 20.14% in its net profit at Rs 241.24 crore for the quarter under review as compared to Rs 302.08 crore for the same quarter in the previous year. Total income of the company decreased by 1.91% at Rs 1110.03 crore for Q2FY23 as compared Rs 1131.67 crore for the corresponding quarter previous year.

The acquisition provides Gland Pharma access to leading know-how and development capabilities in sterile forms including for ophthalmic gel, needleless injectors and hormones

Gland Pharma through its wholly owned subsidiary -- Gland Pharma International PTE, Singapore has entered into a Put Option agreement to acquire 100% of Cenexi Group for an equity value not exceeding Euro 120 million (Enterprise Value of Euro 230 million).

Founded in 2004, Cenexi, along with its Subsidiaries, is engaged primarily in the business of Contract Development & Manufacturing Organisation (CDMO) of pharmaceutical products with expertise in sterile liquid and lyophilized fill-finished drug, including capabilities on oncology and complex products. It has presence across four manufacturing sites in Europe which include three sites in France and one site in Belgium.

Gland Pharma has a strategic focus on expanding its CDMO offerings in the European market and build a manufacturing presence in the market. The acquisition provides Gland Pharma access to leading know-how and development capabilities in sterile forms including for ophthalmic gel, needleless injectors and hormones. Gland Pharma’s ability to support future investments in expanding manufacturing footprint will help build Cenexi as a major CDMO player in the European market. Gland and Cenexi can leverage their long- standing customer relationships to generate synergistic benefit for both entities along with helping Gland enter the branded CDMO space.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Earlier, the Pre-Market Inspection covering US FDA’s Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) was conducted between August 22-25, 2022

Gland Pharma has received the Establishment Inspection Report (EIR) from the Office of Product Evaluation and Quality Center for Devices and Radiological Health, US FDA indicating closure of the inspection at Dundigal Facility in Hyderabad. Earlier, the Pre-Market Inspection covering US FDA’s Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) at the company’s Dundigal Facility at Hyderabad was conducted from  August 22, 2022 to  August 25, 2022. The company had received 1 observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Total consolidated income of the company decreased by 9.85% to Rs 999.80 crore for Q3FY23

Gland Pharma has reported results for third quarter ended December 31, 2022.

The company has reported fall of 16.77% in its net profit at Rs 227.54 crore for Q3FY23 as compared to Rs 273.38 crore for the corresponding quarter previous year. Total income of the company decreased by 10.96% to Rs 987.41 crore for the quarter under review as compared to Rs 1,108.99 crore for the same quarter in the previous year.

On the consolidated basis, the company has reported fall of 15.05% in its net profit at Rs 231.95 crore for Q3FY23 as compared to Rs 273.03 crore for the same quarter in the previous year. Total income of the company decreased by 9.85% to Rs 999.80 crore for the quarter under review as compared to Rs 1,108.99 crore for the same quarter in the previous year.

The inspection has been completed with Zero observations

The United States Food and Drug Administration (USFDA) has conducted an inspection at Gland Pharma’s API Facility at JNPC, Visakhapatnam from January 23, 2023 to January 27, 2023 and has been completed with Zero observations.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

The expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places

Gland Pharma is planning to invest Rs 400 crore to create additional capabilities in its existing facility at Genome Valley in Telangana to manufacture biologicals, biosimilar, antibodies and recombinant Insulin.

The expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places. The company had established their biopharmaceutical facility in February last year at Genome Valley with an investment of Rs 300 crore to manufacture vaccines, biologicals, biosimilar, antibodies and others. The expanded site is envisaged to meet the national and international regulations to be followed in the manufacturing of the biological products as applicable and shall be built under the GMP guidelines applicable for the respective product lines.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.